Marina

#MBC research & health #advocate| Evidence-based complimentary #integrative medicine | #bcsm

[Paolo Tarantino @PTarantinoMD]

I usually share the latest evidence. Many articles, however, can be impactful long after publication. I will start sharing some in a new feature: #AgelessGems💎. The first: a review by @GeorgeSledge51 on curing MBC. Thought provoking, balanced, unmissable. https://t.co/tdeTek3H2y

[GRASP @GRASPtweets]

We’ve got another BEGINNER TRACK walkthrough for you! RSVP today and join Scientist Erin Howe, PhD for a deeper dive into racial and health disparities, side effects, and symptom management.
https://t.co/dhcJTThPVt
#sabcs #sabcs2025 #GRASP #GRASPPosterWalkthrough #beginnertrack

[Giampaolo Bianchini @BianchiniGP]

🔥 A 25-year paradigm challenged in early BC: lidERA shows a giredestrant, a next generation oral SERD, outperforming aromatase inhibitors

iDFS HR 0.70
DDFS HR 0.69

This is really a breakthrough❗️

My take home on clinical implications
👉 High risk: CDK4/6-AI remains standard (more mature trial results). CAMBRIA 2 will define the role of CDK4/6-SERD combo
👉 Intermediate/high risk: SERD might be preferred (with more mature data) to CDK4/6. Is combo better? What about sequencing them (CAMBRIA1, EMBER4, ELEGANT)?
👉Intermediate risk: SERD preferred to CDK4/6

[Sara Tolaney @stolaney1]

Lidera is a big step forward with a new endocrine agent in early-stage ER+ breast cancer

Lots of questions to address, but so important for patients!!!

@OncoAlert #SABCS25

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

HER2CLIMB-05 shows addition of tucatinib to maintenance HP, after median 6 cycles THP, improved mPFS 8.6 mos to 24.9 mos. Benefit more pronounced in HR-, but HR+ benefits as well. #SABCS25 @ErikaHamilton9 @OncoAlert

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

A new chemo free maintenance option for patients with HR+ & HR- HER-2 + disease in the 1st line setting post induction chemo that can provide a meaningful benefit in excess of 2 years is a win for our patients!

@SABCSSanAntonio @OncBrothers @OncoAlert @SarahCannonDocs

[Paolo Tarantino @PTarantinoMD]

The billion dollar question: should we sequence ADCs for treating MBC? Proud to join @JoshDragoMD in this @NEJM debate, where we review the data in support and against the sequential use of ADCs. Open access — read it here: https://t.co/Czm66bL7vF

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

WOW! 🤩

Just fantastic to see this slide showing visually what we all know.

Pace of improvement in breast cancer is fast 🏎️!

👏 to all researchers, participants on trials, and our @FDAOncology colleagues who do an unbelievable amount of work for these approvals!

#SABCS25

[Paolo Tarantino @PTarantinoMD]

@ErikaHamilton9 presents primary results from HER2CLIMB-05: adding tucatinib to 1L maintenance HP significantly improved PFS; most benefit in ER-/HER2+ disease (delta 12 mo). More diarrhea and liver tox with tucatinib. New SoC maintenance option after induction for ER-/HER2+ MBC!

[Paolo Tarantino @PTarantinoMD]

In our retrospective Flatiron data presented at #SABCS24, T-DM1 did seem to outperform a second topo1 ADC after progression on prior T-DXd.

[Paolo Tarantino @PTarantinoMD]

Evolution of HER2 testing over 40 yrs.

IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging.

We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25.

Stay tuned.

https://t.co/ZcH1fAjpJd

[Paolo Tarantino @PTarantinoMD]

We have good evidence that leaving lymph nodes behind does not necessarily compromise outcomes. Could we push the limit & leave the tumor unresected in some responders? Early days, but fascinating concept. Congrats to the authors for this important report! https://t.co/tt53fNj6rW

[Oncology Brothers @OncBrothers]

Treatment Algorithm: This is the algorithm we’ve used during our 🗣️ w/ @KalinskyKevin for HR+ #BreastCancer!

#OncTwitter #bcsm #MedTwitter @CancerNetwrk @OncoAlert

[Abigail Johnston @AMJohnston1315]

The HMV program has given so many of us an entree into #mbc advocacy — for anyone living with MBC, I highly recommend it! #bcsm

[Ilana Schlam @IlanaSchlam]

Wrapping up another fantastic #SABCS!

Amazing, practice-changing data were presented.

I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!

#SABCS24 @OncoAlert

[Abigail Johnston @AMJohnston1315]

Minimum effective dose specific to tumor biology!? Yes please! #sabcs24 #SABCS2024 @VGoldbergOMBCL

[Paolo Tarantino @PTarantinoMD]

Small preview from Wednesday’s #SABCS24 session on the future of ADCs

Question: what do all these ongoing phase 3 ADC trials have in common?

🗓️ Dec 11, 3.30 pm, Hemisfair Ballroom 1-2

[Christine Hodgdon @christeeny513]

Really proud of my work wife (@itsnot_pink) filling the shoes of the late Anne Loeser - the driving force & founder of @the_rightdose. She leaves a legacy that improves the lives of MBC patients who are on treatment indefinitely through drug dose optimization.

#SABCS2024 #bcsm

[Dr. Kelly Shanahan @stage4kelly]

There is an ongoing trial (STOPHER2) to look at stopping tx in people with HER2+ MBC who have been NED for a while, and there has been a study looking at changes in ctDNA with time in ER+ but I’m not aware of one looking at stopping tx if ctDNA undetectable . #SABCS24

[Elisa Agostinetto @ElisaAgostinett]

Did Michelangelo paint a woman with breast cancer in the Sistine Chapel in Rome?🇮🇹
Nice article in @TheBreastOnline👇🏻

The breast has consistently held a significant role in artistic representations and, in this case, also in its pathologies

@OncoAlert

https://t.co/rAzleHosz2